MedPath

ââ?¬Å?To compare the Effectiveness and Safety between Thalidomide and Azathioprine in type two lepra reaction: A Randomized Controlled Trialââ?¬?

Phase 3
Conditions
Health Condition 1: A309- Leprosy, unspecified
Registration Number
CTRI/2022/09/045482
Lead Sponsor
Deepak Kumar Sahu
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

i.Patients with severe ENL of any gender and age >18 years.

ii.Patients willing to participate and willing to follow up for nine months

Exclusion Criteria

i.Patients with known immunosuppression

ii.Patients with severe ENL on any steroid-sparing agents within the last one month

iii.Pregnancy and lactation

iv.Patients with a history of hypersensitivity to thalidomide or azathioprine

v.Patients with hemoglobin less than 10 gm/dl

vi.Patients with HIV, Hepatitis B and C infection.

vii.Patients who will deny giving consent to the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The proportion of patients achieving remission at six month and nine months (Remission is defined as subsidence of all features of ENL with ENL International Study Group Severity Scale score of zero when the patient is off prednisolone or minimal prednisolone dose of 10mg or less)Timepoint: six month and nine months
Secondary Outcome Measures
NameTimeMethod
umber of ENL flaresTimepoint: Nine months;Change in DLQI from the baselineTimepoint: end of nine month;Pathological differences between acute versus chronic/recurrent ENLTimepoint: nine months;Side effect profiles (frequency, nature and severity)Timepoint: within nine months;The correlation between EESS( ENLIST ENL Severity Score) and serum interferon-gamma levels <br/ ><br>NB: Optional subject to thesis grant approveTimepoint: nine months;The cumulative dose of prednisoloneTimepoint: nine months;Time to ENL flareTimepoint: within nine months;Time to initial remissionTimepoint: within nine months
© Copyright 2025. All Rights Reserved by MedPath